Changes in use of hormonal long‐acting reversible contraceptive methods in Australia between 2006 and 2018: A population‐based study Luke E. Grzeskowiak, Helen Calabretto, Natalie Amos, Danielle Mazza, Jenni Ilomaki ANZJOG First published: 23 October 2020, Abstract: Background Long‐acting reversible contraceptives (LARCs) are promoted internationally as a key strategy for reducing unintended...
July/August 2020 The Therapeutic Goods Administration (TGA) advises: Consumers and health professionals are advised that there is a shortage of oral contraceptive pills containing the combination ethinylestradiol and norethisterone. The affected products are: Brevinor – norethisterone 0.5 mg and ethinylestradiol 35 micrograms Norimin – norethisterone 0.5 mg and ethinylestradiol 35...
Marie Stopes Australia, Updated 17 April 2020 Situational Report: Sexual and Reproductive Health Rights in Australia – A request for collaboration and action to maintain contraceptive and abortion care throughout the SARS-COV-2 / COVID-19 pandemic Executive Summary We are in a context of increased risk of unplanned pregnancy, reproductive coercion, sexually transmitted infections, lack of...
Hepatitis Australia, 3 April 2020 Hepatitis Australia warmly welcomes recent changes to the Pharmaceutical Benefits Scheme (PBS) allowing authorised Nurse Practitioners to prescribe hepatitis B and hepatitis C medicines under the Highly Specialised Drugs (s100) Program. Both hepatitis B and hepatitis C are under-treated and without improvement in a range of areas Australia risks falling short of...
Australian Federation of AIDS Organisations (AFAO), March 30th 2020 From 1 April 2020 Truvada for HIV treatment and for pre-exposure prophylaxis (PrEP) will no longer be available through the Pharmaceutical Benefits Scheme (PBS). There are alternatives to Truvada for PrEP in Australia. Community members eligible for PrEP can access generic versions of Truvada supplied by Apotex, Mylan and Lupin...
NAPWHA, May 2019 This NAPWHA report is an analysis drawing together several years’ worth of data from the main pharmaceutical industry suppliers of compassionate access antiretroviral (ARV) therapy in Australia and combines this with, for the first time, data from the State and Territory jurisdictions to produce the most accurate estimate to-date of the number of Medicare ineligible PLHIV in...